



## Diagonal Bio expands its testing panel for horses with EHV-5 detection

Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces the expansion of its equine diagnostic testing panel to include the detection of Equine Herpesvirus type 5 (EHV-5), following the recommendation of Daniel Redén – Diagonal Bio's marketing partner and a renowned horse trainer. Diagonal Bio successfully developed, tested, and validated in-house the EHV-5 detection capability within three weeks.

Diagonal Bio announced on 3<sup>rd</sup> October 2024 that horse trainer Daniel Redén from StallZet will conduct a pilot using the LAMPlify® platform to test for equine viruses. This collaboration focuses on supporting Redén's efforts to maintain the health and fitness of his horses for competition. During the ongoing pilot, Diagonal Bio promptly addressed Redén's request for EHV-5 testing by developing and validating this new testing panel for EHV-5 detection within three weeks, aiming to meet the needs of the equine industry more comprehensively.

EHV-5 is more commonly found in horses than other strains such as EHV-1 and EHV-4. Infected horses can remain asymptomatic, making the virus harder to detect through traditional methods.

"I have worked closely with Diagonal Bio to ensure we can efficiently identify and manage various viruses in our horses. The introduction of the EHV-5 marker is another step in ensuring we can proactively handle potential infections, which traditionally is hard to detect. I avoid competing with horses that test positive for viruses, which makes early detection important effective health management" – Daniel Redén, horse trainer at StallZet

"Our collaboration with Daniel Redén continues to drive innovation in equine health diagnostics and foremost in LAMPlify®. I am impressed that our team could introduce the EHV-5 testing that quickly, within a three-week frame, which for me is yet another example of how we're meeting the needs of top trainers and the broader equine industry" – Karin Wehlin, CEO of Diagonal Bio AB (publ)

*This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on January 14, 2025, at 22:00 CET.*

### For more information, please contact:

Karin Wehlin, CEO  
Phone: +46 (0)70 305 24 88  
E-mail: kw@diagonalbio.com

### Certified Adviser

Svensk Kapitalmarknadsgranskning AB  
E-mail: ca@skmg.se

### About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.